Propafenone is a potent antiarrhythmic drug, which is widely used in the treatment of ventricular and supraventricular arrhythmias. 1 It blocks the fast inward sodium current in all cardiac and other excitable tissues, like the central nervous system. Propafenone also has some β-blocking action, much less than that of propranolol, and a weak calcium-channelblocking effect. 2 Propafenone undergoes extensive first-pass metabolism by the liver to form several metabolites. The main metabolic pathway of propafenone is ring hydroxylation to 5-OH-propafenone, being primarily mediated by CYP2D6. This pathway is polymorphically expressed in humans and is under genetic control, co-segregating with a well-described debrisoquine oxidation polymorphism, 3 such that poor metabolizers can be distinguished from extensive metabolizers. 4 An additional route of propafenone metabolism is N-demethylation to N-despropylpropafenone, which is primarily mediated via CYP3A4 and CYP1A2.
Introduction
Propafenone is a potent antiarrhythmic drug, which is widely used in the treatment of ventricular and supraventricular arrhythmias. 1 It blocks the fast inward sodium current in all cardiac and other excitable tissues, like the central nervous system. Propafenone also has some β-blocking action, much less than that of propranolol, and a weak calcium-channelblocking effect. 2 Propafenone undergoes extensive first-pass metabolism by the liver to form several metabolites. The main metabolic pathway of propafenone is ring hydroxylation to 5-OH-propafenone, being primarily mediated by CYP2D6. This pathway is polymorphically expressed in humans and is under genetic control, co-segregating with a well-described debrisoquine oxidation polymorphism, 3 such that poor metabolizers can be distinguished from extensive metabolizers. 4 An additional route of propafenone metabolism is N-demethylation to N-despropylpropafenone, which is primarily mediated via CYP3A4 and CYP1A2. 5 Five hydroxy-propafenone has been shown to exert pharmacologic activity comparable to that of the parent drug. 6 Although N-despropylpropafenone exerted antiarrhythmic activity in animal experiments, 7 relatively little is known about its pharmacokinetics and pharmacodynamics in humans. The metabolic pathway of propafenone is illustrated in Fig. 1 .
The specific metabolism of propafenone, its potential drug-drug interactions and its widespread use have stimulated efforts to develop routine assays for this drug and its metabolites in human serum. Several chromatographic methods have been reported for the determination of propafenone and 5-OH-propafenone in biological matrices, including highperformance liquid chromatography (HPLC) [8] [9] [10] [11] [12] [13] [14] [15] 18 and gas chromatography. 16, 17 For HPLC assays, different modes of detection have been employed, including UV [8] [9] [10] [11] [12] [13] [14] [15] and fluorescence with precolumn derivatization. 18 Most of these methods have only been validated for propafenone, itself, or propafenone and 5-OH-propafenone. The resolution of N-despropylpropafenone, which is probably co-eluted under reported procedures, was rarely investigated.
Among the methods described so far, only a few allow for the determination of the serum or plasma concentrations of propafenone and its main metabolites in a single run. [19] [20] [21] The Fig. 1 Metabolic pathway of propafenone.
procedure, based on high-performance liquid chromatography with mass spectrometry, is highly sensitive and specific, but involves equipments not generally available in a clinical set. 21 The major drawbacks of the mentioned methods are using complicated labor-and time-intensive sample-processing methods with several liquid-liquid extraction steps or solidphase extraction as sample preparation procedures, [19] [20] [21] long elution times, 19 poor sensitivity and recovery specially for N-despropylpropafenone. 20 This paper describes a rapid and specific HPLC method with UV detection for the simultaneous analysis of propafenone and its two major metabolites using direct protein precipitation. The developed method was successfully applied to assess the pharmacokinetics of propafenone and its two major metabolites following the oral administration of a single 300 mg dose of propafenone hydrochloride to three healthy male volunteers.
Experimental

Materials
Propafenone, 5-OH-propafenone hydrochloride and N-despropylpropafenone fumarate (Knoll, Ludwigshafen, Germany) were kindly donated by Dr. Ute Hofmann (Dr. Margarete Fischer-Bosch-Institut fur Klinische Pharmakologie, Stuttgart, Germany).
Acetonitrile (HPLC-grade), potassium dihydrogenphosphate, and orthophosphoric acid (85%), zinc sulfate and methanol (HPLC-grade) were purchased from Merck (Darmstadt, Germany). Double-distilled water was used throughout the study.
Preparation of standard solutions
Standard stock solutions (100 µg ml -1 as free base) of each product were prepared separately in methanol and stored at -20˚C. Working solutions were prepared daily from these stock solutions by dilution with distilled water.
Apparatus and chromatographic condition
The chromatographic apparatus consisted of a low-pressure gradient HPLC pump, a UV variable-wavelength detector and an online degasser, all from Knauer (Berlin, Germany). A Reodyne Model 7725i injector with a 200 µl loop was used. The data were acquired and processed by means of Urochrome chromatography software (Knauer, Berlin, Germany). Chromatographic separation was achieved on a tracer excel reversed-phase column (C18, 25 × 0.46 cm i.d., 5 µm particle size) from Teknokroma (Spain) protected with a C18 guard column (Teknokroma, Spain).
A gradient separation was used with solvent A being a phosphate buffer (pH = 3, 0.01 M) and acetonitrile (72:28) and solvent B being a phosphate buffer (pH = 3, 0.01 M) and acetonitrile (67:33). The gradient steps were as follows: 0 -7 min, isocratic at 100% solvent A; changed to solvent B over 2 min; isocratic at 100% solvent B up to 17 min; changed to solvent A over 1 min, kept constant for 5 min to re-equilibrate. Total analysis time was 23 min at a flow rate of 1.7 ml min -1 at room temperature (25˚C). The eluate was monitored with a UV detector set at wavelength of 210 nm and the compounds were quantified using their peak height.
Sample preparation
An aliquot of 250 µl serum was precipitated with 50 µl of a zinc sulfate solution (35%) and 150 µl methanol, vortexed for 1 min and centrifuged for 10 min at 15800g in a 5415C eppendrof centrifuge. A clear supernatant was transferred into another eppendrof tube, and 200 µl of this was injected on to an HPLC column.
Preparation of calibration standards
During validation, eight point calibration standards were freshly prepared in serum for each run, covering a concentration range of 10 -750 ng ml -1 for each compound. Calibration data were acquired by plotting the peak height of the analytes against the concentration of the calibration standards, followed by a linear-regression analysis.
Selectivity and specificity
Control human serum, obtained from ten healthy subjects, was assessed by the procedure as described above and compared with respective spiked serum samples to evaluate selectivity of the method.
Several cardiovascular agents like amiodarone, verapamil, losartan, propranolol, atenolol, enalapril and captopril were also assessed for potential interferences.
Accuracy, precision, limit of quantification (LOQ) and recovery
The accuracy, between-day and within-day, precisions of the method were determined for each compound according to FDA guidance for bioanalytical method validation. 22 Seven and five replicate spiked serum samples were assayed between-day and within-day, respectively, at four different concentrations (20, 100, 500 and 750 ng ml -1 ) for each analyte. The concentrations were calculated using calibration curves prepared and analyzed in the same run. The accuracy was calculated as the deviation of the mean from the nominal concentration. The between-day and within-day precisions were expressed as the relative standard deviation of each calculated concentration. For the concentration to be accepted as LOQ, the percent deviation from the nominal concentration (accuracy) and the relative standard deviation must be ±20% and less than 20%, respectively, considering at least five-times the response compared to the blank response. The average recovery of each compound was determined by comparing the peak-height obtained after injection of the processed QC samples with those achieved by direct injection of the same amount of drug in distilled water at different concentrations (ten samples for each concentration level).
Application of the method
Three male volunteers were included in this study. The study protocol was approved by the Ethics Committee of Tehran University of Medical Sciences and written informed consent was obtained from the volunteers. Volunteers were not allowed to take any other medication for two weeks before and throughout the study. Those with a history of cardiovascular disorders were excluded from participitation in the study. The volunteers received 300 mg of propafenone hydrochloride tablets (Knoll) as a single oral dose after an overnight fast. The intake of food was delayed for 3 h after medication. Peripheral venous blood samples were taken from each volunteer immediately before, and at 0.5, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12 and 24 h after administration of propafenone. Serum samples were stored at -20˚C until analysis for a maximum of 1 month.
Calculation of pharmacokinetic parameters
Serum concentration-time curves of propafenone and its metabolites were evaluated by non-compartmental analysis.
The maximum plasma concentration, Cmax, and the time to Cmax 
Results and Discussion
Selectivity and chromatography
Various pH values of aqueous buffer, proportions of acetonitrile and phosphate buffer and flow rates were examined to obtain the best separation within the analytes, both from each other and from endogenous compounds. Although a mobile phase containing phosphate buffer (0.01 M, pH = 3): acetonitrile (72:28) met the above requirement, it was still not satisfactory due to the resulting broad and short propafenone peaks, which yielded quantification limits of higher than 50 ng/ml, not suitable for pharmacokinetic studies. Although the propafenone peak shape, and in consequence its quantification limit, was highly affected by the composition of acetonitrile in mobile phase, it was not possible to add more acetonitrile to the mentioned mobile phase without losing resolution between 5-OH and N-despropylpropafenone. Therefore, a gradient elution was chosen to have sharper peaks, and in consequence a lower limit of quantification.
Separation achieved using the experimental conditions of the present assay for propafenone and its main metabolites are presented in Fig. 2 . Selectivity was indicated by the absence of any endogenous interference at retention times of the peak of interest, as evaluated by chromatograms of control human serum and serum spiked with three compounds. The retention times for 5-OH-propafenone, N-despropylpropafenone and propafenone were 7.18, 7.22, and 14.85 min, respectively. An unidentified peak (a) was detected in the serum of the volunteers having received propafenone. As such, the unidentified peak is likely to correspond to another propafenone hydroxylated derivate, 5-hydroxy-4 methoxypropafenone, which has been reported previously. 19, 23 The system suitability parameters for the method were as follows: the theoretical plates for 5-OH and N-despropylpropafenone >11800 and for propafenone >40900; the resolutions between each two consecutive peak of analytes as well as the unidentified peak (a) were >1.5. None of the drug mentioned above interfered with the analytes peaks. No change in the column efficiency and back pressure was observed over the entire study time. Accordingly, at least three hundred samples/column could be analyzed without any significant loss of resolution.
Linearity
Eight point calibration curves for propafenone and its metabolites on separate days were linear over the concentration range of 10 -750 ng ml -1 . The equations for the means (n = 6) of six standard curves are: for propafenone, y = 0.025x + 0. 
Limit of quantification
LOQs, as previously defined, were 10 ng ml -1 for each compound. The LOQ values for three analytes are reported in Table 1 .
Recovery, accuracy and precision
The recoveries of propafenone and its metabolites were evaluated by different pretreatment methods, like different volumes of methanol, acetonitrile, acetone, trichloroacetic acid, perchloric acid, zinc sulfate and a mixture of them for deproteinization. Although the addition of three volumes of methanol to one volume of serum yielded recoveries of higher than 70%, it was not satisfactory because of higher LOQs. Lower LOQs and higher recoveries were achieved by adding zinc sulfate or perchloric acid to methanol. However, the former was better due to harder precipitates.
The results from the validation of the method in human serum are listed in Table 2 . The method proved to be accurate and precise; the accuracy at four concentration levels ranged from 91.5 -111.3% for all compounds. The within-day and betweenday precision ranged from 1.4 -8.1% and 4.2 -11.5%, respectively, for all analytes. For this reason, an internal standard was not used. The absolute recoveries ranged from 98.3 -103.2%.
Stability
Stability was demonstrated for spiked serum samples stored at -20˚C for up to two months, at ambient temperature for at least 10 h and four freeze-thaw cycles. The stability of processed samples was also demonstrated over 10 h. The stability of stock solutions stored at -20˚C was determined for up to 1 month by injecting appropriate dilutions of stocks in distilled water on day 1, 15 and 30 and comparing their peak heights with fresh stock prepared on the day of analysis. Samples were considered to be 
Application of the method
To apply the developed and validated method, the pharmacokinetics of propafenone and its metabolites was assessed in three healthy volunteers. The subjects were treated with 300 mg of propafenone hydrochloride. Plots of the propafenone, 5-OH-propafenone and N-despropylpropafenone serum concentrations of one volunteer as a function of time following oral dosing is shown in Fig. 3 .
The pharmacokinetic parameters of propafenone and its metabolites derived by non-compartmental analysis are summarized in Table 3 .
Conclusion
The method presented here describes a simple, specific and reproducible human serum assay for the determination of propafenone and its major metabolites in a single run. The possibility of measuring N-despropylpropafenone in addition to 5-hydroxypropafenone and propafenone extends the method to enzymes other than CYP2D6. It allows for the evaluation of Ndemethylation rates, which are considered to be indicators of CYP3A4 activity. Moreover, it further helps to gain insights into the pharmacologic aspects of N-despropylpropafenone in vivo. The gradient elution used in this procedure decreased the propafenone quantification limit to an amount suitable for pharmacokinetic studies, besides preserving the selectivity of the analytes. A small volume of serum is needed for sample preparation, and still the LOQ values (10 ng ml -1 ) are lower than the previously published methods, which were able to measure propafenone and its two metabolites. 19, 20 The method also applies a simple and rapid sample treatment instead of rather laborious liquid-liquid or solid-phase extraction as part of the chromatographic procedure, yielding better recoveries, especially for N-despropylpropafenone, thereby saving time and expense for sample preparation. The method was found to be suitable to be currently used for pharmacokinetic studies in humans. Table 2 Between-and within-day variability, accuracy, and recovery for determination of propafenone, 5-OH-propafenone, and N-despropylpropafenone Within-day variability (n = 5) Accuracy, % Recovery (n = 10) Between-day variability (n = 7) Concentration/ ng ml 
